Список литературы

1. Gakis G., Witjes J.A., Comp rat E. et al. EAU guidelines on primary urethral carcinoma. Eur Urol 2013; 64(5): 823-30.

2. Medina P rez M., Valero Puerta J., S nchez Gonz lez M. et al. Squamous carcinoma of the male urethra, its presentation as a scrotal abscess. Arch Esp Urol 1999; 52: 792-4.

3. Van de Voorde W., Meertens B., Baert L., Lauweryns J. Urethral squamous cell carcinoma associated with urethral stricture and urethroplasty. Eur J Surg Oncol 1994; 20(4): 478-83.

4. Sawczuk I., Acosta R., Grant D., White R.D. Post urethroplasty squamous cell carcinoma. N Y State J Med 1986; 86(5): 261-3.

5. Colapinto V., Evans D.H. Primary carcinoma of the male urethra developing after urethroplasty for stricture. J Urol 1977; 118(4): 581-4.

6. Mohanty N.K., Jolly B.B., Saxena S., Dawson L. Squamous cell carcinoma of perineal urethrostomy. Urol Int 1995; 55(2): 118-9.

7. Mohan H., Bal A., Punia R.P., Bawa A.S. Squamous cell carcinoma of the prostate. Int J Urol 2003; 10(2): 114-6.

8. Arva N.C., Das K. Diagnostic dilemmas of squamous differentiation in prostate carcinoma case report and review of the literature. Diagn Pathol 2011; 6: 46.

9. Zhang M., Adeniran A.J., Vikram R. et al. Carcinoma of the urethra. Hum Pathol 2018; 72: 35 - 44.

10. Thomas A.A., Rackley R.R., Lee U. et al. Urethral diverticula in 90 female patients: a study with emphasis on neoplastic alterations. J Urol 2008; 180(6): 2463-7.

11. Libby B., Chao D., Schneider B.F. Non-surgical treatment of primary female urethral cancer. Rare Tumors 2010; 2(3): e55.

12. Altman D., Rogers R.G., Yin L. et al. Cancer risk after midurethral sling surgery using polypropylene mesh. Obstet Gynecol 2018; 131(3): 469-74.

13. Visser O., Adolfsson J., Rossi S. et al. Incidence and survival of rare urogenital cancers in Europe. Eur J Cancer 2012; 48(4): 456-64.

14. Swartz M.A., Porter M.P., Lin D.W., Weiss N.S. Incidence of primary urethral carcinoma in the United States. Urology 2006; 68(6): 1164-8.

15. WHO Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs (IARC WHO Classification of Tumours). Eble J.N., Sauter G., Epstein J., Sesterhenn I. (eds.) Lyon, 2004.

16. TNM classification of malignant tumors. Ed. J.D. Brierley et al. Wiley/Blackwell, 2017. P. 208.

17. Гриднева Я.В. Дисс. канд. мед. наук "Злокачественные новообразования мочеиспускательного канала (клиника, диагностика, лечение)". М., 2005.

18. EAU Guidelines on primary urethral carcinoma (2022) [Электронный ресурс]//European Association of Urology: [сайт]. URL: https://uroweb.org/guideline/primary-urethral-carcinoma/(дата обращения: 16.02.2022).

19. Del Gaizo A., Silva A.C., Lam-Himlin D.M. et al. Magnetic resonance imaging of solid urethral and peri-urethral lesions. Insights Imaging. 2013; 4(4): 461 - 469.

20. Gakis G., Morgan T.M., Efstathiou J.A. et al. Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinoma. World J Urol. 2016; 34(1): 97 - 103.

21. Ochi T., Ozawa A., Tanji N. et al. Gemcitabine and cisplatin therapy in advanced or metastatic urothelial cancer: comparison of side effect with MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin). Nihon Hinyokika Gakkai zasshi. The Japanese Journal of Urology 2006; 97(6): 777-81.

22. Dayyani F., Pettaway C.A., Kamat A.M. et al. Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with urethral carcinomas referred to medical oncologists. Urologic Oncology: Seminars and Original Investigations. Elsevier. 2013; 31(7): 1171 - 1177.

23. Soloway M. S., Ishikawa S., Taylor T., Ezell G. M-VAC or MVC for the treatment of advanced transitional cell carcinoma: Metastatic, induction, and adjuvant. Journal of Surgical Oncology, 1989; 42(S1): 40 - 45.

24. Bellmunt J., von der Maase H., Mead G.M. et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. Journal of Clinical Oncology. 2012; 30(10): 1107-13.

25. De Santis M., Bellmunt J., Mead G. et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II-results of EORTC study 30986. Journal of Clinical Oncology. 2009; 27(33): 5634-9.

26. Kim Y.R., Lee J.L., You D. et al. Gemcitabine plus split-dose cisplatin could be a promising alternative to gemcitabine plus carboplatin for cisplatin-unfit patients with advanced urothelial carcinoma. Cancer chemotherapy and pharmacology. 2015; 76(1): 141 - 153.

27. Izumi K, Iwamoto H., Yaegashi H. et al. Gemcitabine Plus Cisplatin Split Versus Gemcitabine Plus Carboplatin for Advanced Urothelial Cancer With Cisplatin-unfit Renal Function. In vivo 2019; 33(1): 167 - 172.

28. Holmsten K., Jensen N.V., Mouritsen L.S. Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM). Eur J Cancer. 2019 Oct 21. pii: S0959-8049(19) 30726-9. doi: 10.1016/j.ejca.2019.08.033

29. Gakis G., Morgan T. M., Daneshmand S. et al. Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma. Annals of Oncology. 2015; 26(8): 1754 - 1759

30. Hussein A., Benedetto P., Sridhar K. Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas. Cancer. 1990 Feb 1; 65(3): 433-8.

31. Cohen M.S., Triaca V., Billmeyer B. et al. Coordinated chemoradiation therapy with genital preservation for the treatment of primary invasive carcinoma of the male urethra. J Urol 2008; 179(2): 536-41; discussion 541.

32. Hara I., Hikosaka S., Eto H. et al. Successful treatment for squamous cell carcinoma of the female urethra with combined radio- and chemotherapy. Int J Urol 2004; 11(8): 678-82.

33. Kent M., Zinman L., Girshovich L. et al. Combined chemoradiation as primary treatment for invasive male urethral cancer. J Urol 2015; 193(2): 532-7.

34. Silver J.A., Baima J. Cancer prehabilitation: an opportunity to decrease treatmentrelated morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am J Phys Med Rehabil 2103; 92: 715-27.

35. Hulzebos E.H., Helders P.J., Favie N.J. et al. Preoperative intensive inspiratory muscle training to prevent postoperative pulmonary complications in high-risk patients undergoing CABG surgery: a randomized clinical trial. JAMA 2006; 296(15): 1851-7.

36. Tsimopoulou I., Pasquali S., Howard R. et al. Psychological prehabilitation before cancer surgery: a systematic review. Ann Surg Oncol 2015; 22(13): 4117-23. DOI: 10.1245/s10434-015-4550-z.

37. Swarm R., Abernethy A.P., Anghelescu D.L. et al. Adult cancer pain. J Natl Compr Canc Netw 2010; 8: 1046-86.

38. Oren R., Zagury A., Katzir O. et al. Musculoskeletal cancer surgery. Dordrecht: Springer, 2013. Pp. 583 - 593.

39. Position statement of the National Lymphedema Network: the diagnosis and treatment of lymphedema. NLN Medical Advisory Committee 2011: 1 - 19.

40. Segal R., Zwaal C., Green E. et al. Exercise for people with cancer guideline development G: Exercise for people with cancer: a systematic review. Curr Oncol 2017; 24(4): e290 - 315.

41. Boyd C., Crawford C., Paat C.F. et al. Evidence for massage therapy working G: the impact of massage therapy on function in pain populations-a systematic review and meta-analysis of randomized controlled trials: part II, cancer pain populations. Pain Med 2016; 17(8): 1553-68.

42. Mehling W.E., Jacobs B., Acree M. et al. Symptom management with massage and acupuncture in postoperative cancer patients: a randomized controlled trial. J Pain Symptom Manage 2007; 33(3): 258-66.

43. Kessels E., Husson O., van der Feltz-Cornelis C.M. The effect of exercise on cancer-related fatigue in cancer survivors: a systematic review and meta-analysis. Neuropsychiatr Dis Treat 2018; 14: 479-94.

44. Bensadoun R.J., Nair R.G. Low-level laser therapy in the management of mucositis and dermatitis induced by cancer therapy. Photomed Laser Surg 2015; 33(10): 487-91.

45. Stout N.L., Baima J., Swisher A.K. et al. A systematic review of exercise systematic reviews in the cancer literature (2005-2017). PM R 2017; 9(9S2): S347-84.

46. Mustian K.M., Alfano C.M., Heckler C. et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol 2017; 3(7): 961-8.

47. Kinkead B., Schettler P.J., Larson E.R. et al. Massage therapy decreases cancer-related fatigue: Results from a randomized early phase trial. Cancer 2018; 124(3): 546-54.

48. Streckmann F., Zopf E.M., Lehmann H.C. et al. Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med 2014; 44(9): 1289-304.

49. Kleckner I.R., Kamen C., Gewandter J.S. et al. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer 2018; 26(4): 1019-28.

50. Lee J.M., Look R.M., Turner C. et al. Low-level laser therapy for chemotherapy-induced peripheral neuropathy. J Clin Oncol 2012; 30(15 suppl): 9019.

51. Rick O., von Hehn U., Mikus E. et al. Magnetic field therapy in patients with cytostatics-induced polyneuropathy: A prospective randomized placebo-controlled phase-III study. Bioelectromagnetics 2017; 38(2): 85 - 94.

52. Kilinc M., Livanelioglu A., Yildirim S.A., Tan E. Effects of transcutaneous electrical nerve stimulation in patients with peripheral and central neuropathic pain. J Rehabil Med 2014; 46(5): 454-60.

53. Oberoi S., Zamperlini-Netto G., Beyene J. et al. Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. PLoS One 2014; 9(9): e107418.

54. Westphal J.G., Schulze P.C. Exercise training in cancer related cardiomyopathy. J Thorac Dis 2018; 10(suppl 35): S4391-9.

55. Ross M., Fischer-Cartlidge E. Scalp cooling: a literature review of efficacy, safety, and tolerability for chemotherapy-induced alopecia. Clin J Oncol Nurs 2017; 21(2): 226-33.

56. Angenete E, Anger s U, B rjesson M, Ekelund J, Gellerstedt M, Thorsteinsdottir T, Steineck G, Haglind E. Physical activity before radical prostatectomy reduces sick leave after surgery - results from a prospective, non-randomized controlled clinical trial (LAPPRO). BMC Urol. 2016 Aug 16; 16(1): 50.

57. Santa Mina D., Matthew A.G., Hilton W.J. et al. Prehabilitation for men undergoing radical prostatectomy: a multi-centre, pilot randomized controlled trial. BMC Surg. 2014 Nov 13; 14: 89.

58. Wang W, Huang QM, Liu FP, Mao Q. Effectiveness of preoperative pelvic floor muscle training for urinary incontinence after radical prostatectomy: a meta-analysis. BMC Urol. 2014; 14: 99.

59. Azhar RA, Bochner B, Catto J, Goh AC, Kelly J, Patel HD, Pruthi RS, Thalmann GN, Desai M. Enhanced Recovery after Urological Surgery: A Contemporary Systematic Review of Outcomes, Key Elements, and Research Needs. Eur Urol. 2016 Jul; 70(1): 176 - 187.

60. Shin KY, Guo Y, Konzen B, Fu J, Yadav R, Bruera E. Inpatient cancer rehabilitation: the experience of a national comprehensive cancer center. Am J Phys Med Rehabil 2011; 90(5): 63-S68.

61. Liu B., Domes T., Jana, K. Evaluation of an enhanced recovery protocol on patients having radical cystectomy for bladder cancer. Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2018; 12(12): 421-6. Advance online publication.

62. De Almeida E.P.M., De Almeida J.P., Landoni G., Galas F.R.B.G., Fukushima J.T., Fominskiy E., De Brito C.M.M., Hajjar L.A. Early mobilization programme improves functional capacity after major abdominal cancer surgery: A randomized controlled trial. British Journal of Anaesthesia 2017; 119(5): 900-7.

63. Hu C, Zhang H, Wu W, et al.: Acupuncture for Pain Management in Cancer: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med 2016; 1720239: 2016.

64. Silverdale N., Wherry M., Roodhouse A. Massage and reflexology for post-operative cancer cystectomy patients: Evaluation of a pilot service. Complement Ther Clin Pract 2019; 34: 109-12.

65. Shaitelman SF, Cromwell KD, Rasmussen JC, Stout NL, Armer JM, Lasinski BB, Cormier JN. Recent progress in the treatment and prevention of cancer-related lymphedema. CA Cancer J Clin. 2015 Jan-Feb; 65(1): 55 - 81.

66. Borman Р. Lymphedema diagnosis, treatment, and follow-up from the view point of physical medicine and rehabilitation specialists. Turk J Phys Med Rehab 2018; 64(3): 179 - 197.

67. Muzi JL, Look RM., Turner C, Gardiner SK, Wagie T, Douglas J, Sorenson L, Evans L, Kirchner S, Dashkoff C, Garrett K, Johnson N. Low-level laser therapy for chemotherapy-induced peripheral neuropathy. Journal of Clinical Oncology 30, no. 15_suppl (May 2012) 9019 - 9019.

68. Horgan S., O'Donovan A. The Impact of Exercise during Radiation Therapy for Prostate Cancer on Fatigue and Quality of Life: A Systematic Review and Meta-analysis. Journal of Medical Imaging and Radiation Sciences, June 2018Volume 49, Issue 2, Pages 207 - 219.

69. Segal RJ, Reid RD, Courneya KS, Sigal RJ, Kenny GP, Prud'Homme DG, et al. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol 2009; 27: 344-51.

70. Матвеев В.Б., Гринева Я.В. Результаты комбинированного и лучевого лечения рака уретры. Онкоурология 2006; 3: 40 - 44.

71. Powles, T., et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med, 2020; 383: 1218.

72. Bajorin DF, Witjes JA, Gschwend JE, et al. First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab versus placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma. Oral presentation at the 2021 Genitourinary Cancers Symposium (ASCO GU); February 11 - 13, 2021; Virtual Meeting.

73. Touijer A.K., Dalbagni G. Role of voided urine cytology in diagnosing primary urethral carcinoma. Urology 2004; 63(1): 33-5.

74. Barkan G.A., Wojcik E.M., Nayar R., Savic-Prince S., Quek M.L., Kurtycz D.F.I., Rosenthal D.L. The Paris System for Reporting Urinary Cytology: The Quest to Develop a Standardized Terminology. Acta Cytol 2016. 60(3): 185-97.

75. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., Carbone P.P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5(6): 649-55.

76. Karnofsky D.A., Burchenal J.H. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod C. (ed.). Evaluation of chemotherapeutic agents. New York: Columbia University Press; 1949: 191 - 205.

77. Hawker G.A., Mian S., Kendzerska T., French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken) 2011; 63(Suppl 11): S240-52.

78. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45(2): 228-47. doi: 10.1016/j.ejca.2008.10.026

79. Seymour L., Bogaerts J., Perrone A. et al. RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017; 18(3): e143-52. doi: 10.1016/S1470-2045(17) 30074-8. Epub 2017 Mar 2.

80. Coop H. et al. Radical chemoradiotherapy for urethral squamous cell carcinoma: Two case reports and a review of the literature//Case Reports in Urology. - 2013. - Т. 2013.

81. Novakovic AM, Wilkins JJ, Dai H, Wade JR, Neuteboom B, Brar S, Bello CL, Girard P, Khandelwal A. Changing Body Weight-Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma. Clin Pharmacol Ther. 2020 Mar; 107(3): 588 - 596.

82. Bellmunt J. et al. Phase I - II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium//Journal of clinical oncology. - 2000. - Т. 18. - N. 18. - С. 3247 - 3255.

83. Bellmunt J. et al. Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer//European journal of cancer. - 2000. - Т. 36. - С. 17 - 25.